Fig. 7.
Effect of agonist antibodies anti-TRAIL receptors on HL60 viability and CD14 induction.
Cultures were left untreated or were treated with TRAIL (0.2 μg/mL) or antibody anti-TRAIL receptors (TRAIL-R1, TRAIL-R2, TRAIL-R3, TRAIL-R4) for 24 hours. (A) Apoptosis quantitatively evaluated by flow cytometry after PI staining. (B) Percentage of cells expressing surface CD14, determined by flow cytometry. Data represent the means ± SD of 3 separate experiments performed in duplicate.